← Leaderboards
Konstantin Tsoyi
Baylor College Of Medicine
$1,638,129
Attributed
$1,638,129
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $596.2K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,638,129 · 3
By mechanism
K01$654,750 · 1
R01$596,179 · 1
R21$387,200 · 1
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Si-Yi Chen$10,785,586
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroPlayFibroblastsLungMortalityPathogenesisMediatingInterstitial Lung DiseasesProteinsIn VivoMemberMolecularMyofibroblastAttenuatedEnvironmentPulmonary FibrosisTgfb1 GeneAnimal ModelAutomobile DrivingExtracellular MatrixComplicationPhenotypeProductionTherapeutic Intervention
Grant awards (8)
Macropinocytosis and Pulmonary Fibrosis$596,179
R01 · FY2025 · HL · contact PI
Antifibrotic effects of Syndecan-2 and CD148 in Rheumatoid Arthritis Interstitial Lung Disease$130,950
K01 · FY2024 · AR · contact PI
Contribution of Macropinocytosis in fibroblast activation and systemic sclerosis$176,000
R21 · FY2023 · AR · contact PI
Antifibrotic effects of Syndecan-2 and CD148 in Rheumatoid Arthritis Interstitial Lung Disease$130,950
K01 · FY2023 · AR · contact PI
Contribution of Macropinocytosis in fibroblast activation and systemic sclerosis$211,200
R21 · FY2022 · AR · contact PI
Antifibrotic effects of Syndecan-2 and CD148 in Rheumatoid Arthritis Interstitial Lung Disease$130,950
K01 · FY2022 · AR · contact PI
Antifibrotic effects of Syndecan-2 and CD148 in Rheumatoid Arthritis Interstitial Lung Disease$130,950
K01 · FY2021 · AR · contact PI
Antifibrotic effects of Syndecan-2 and CD148 in Rheumatoid Arthritis Interstitial Lung Disease$130,950
K01 · FY2020 · AR · contact PI